Status:
UNKNOWN
Predicting Outcomes From tDCS Intervention in Parkinson' Disease Using Electroencephalographic Biomarkers and Machine Learning Approach: the PREDICT Study Protocol
Lead Sponsor:
Federal University of Paraíba
Collaborating Sponsors:
Universidade Federal do Rio Grande do Norte
Conditions:
Parkinson Disease
Electroencephalogram
Eligibility:
All Genders
40-70 years
Phase:
NA
Brief Summary
Parkinson's disease (PD) is a progressive and disabling neurodegenerative disease, clinically characterized by motor and non-motor symptoms. The potential of the "Transcranial direct current stimulati...
Eligibility Criteria
Inclusion
- Diagnosis of idiopathic Parkinson's disease by a neurologist based on Parkinson's Disease Society Brain Bank (PDSBB) criteria (Hughes et al.,1992)
- Disease staging between 1.5 and 3, according to the modified Hoehn and Yahr scale (Hoehn and Yahr, 1967)
- Regular pharmacological treatment with levodopa (equivalent dose \> 300mg) or taking antiparkinsonian medication such as anticholinergics, selegiline, dopamine agonists (amantadine) and COMT (catechol-O-methyl transferase) inhibitors
- Score of more than 24 points on the Mini-Mental State Examination (Folstein et al., 1975)
Exclusion
- Associated neurological, musculoskeletal and/or cardiorespiratory diseases that could compromise gait;
- alcohol or substance abuse disorders;
- Deep brain stimulation implant;
- History of brain trauma or neurological disease that would interfere with study procedures.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT04819061
Start Date
June 1 2021
End Date
December 31 2021
Last Update
March 26 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.